Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Cyclosporine and Methotrexate Compared with Cyclosporine and Mycophenolate Mofetil as GVHD Prevention Regimens In Allogeneic Stem-Cell Transplantation From Unrelated Donors; Relative Outcomes Are Dependant on Disease Status at Transplantation

Avichai Shimoni, MD, Avital Rand, RN, BSN, Noga Shem-Tov, MD, Izhar Hardan, MD, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler, M.D.

Blood (2010) 116 (21): 2314.

https://doi.org/10.1182/blood.V116.21.2314.2314

Published: 2010

Journal Articles

Fludarabine and Treosulfan Conditioning for Allogeneic Stem-Cell Transplantation; a Dose- Intense Regimen with Limited Toxicity.

Avichai Shimoni, MD, Avital Rand, RN, BSN, Noga Shem-Tov, Izhar Hardan, Yulia Volchek, MD, Ronit Yerushalmi, MD, Arnon Nagler, M.D.

Blood (2010) 116 (21): 3473.

https://doi.org/10.1182/blood.V116.21.3473.3473

Published: 2010

Journal Articles

Second Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine Treosulfan Conditioning Regimen in Patients Previously Treated with Busulfan-Based Regimens; Myeloablation with Acceptable Toxicity.

Avichai Shimoni, MD, Avital Rand, RN, Noga Shem-Tov, MD, Izhar Hardan, Yulia Volchek, MD, Hannah Maayaan, MD, Ronit Yerushalmi, Arnon Nagler, MD

Blood (2009) 114 (22): 2255.

https://doi.org/10.1182/blood.V114.22.2255.2255

Published: 2009

Journal Articles

Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation (SCT) with Fludarabine and Intravenous Busulfan Is Associated with Improved Toxicity Profile and Longer Survival Than Conditioning with Fludarabine and Melphalan in Patients with Chemo-Sensitive Hematological Malignancies.

Avichai Shimoni, MD, Izhar Hardan, MD, Avital Rand, RN, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Arnon Nagler, MD

Blood (2007) 110 (11): 2002.

https://doi.org/10.1182/blood.V110.11.2002.2002

Published: 2007

Journal Articles

Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC).

Avichai Shimoni, MD, Izhar Hardan, MD, Noga Shem-Tov, MD, Avital Rand, RN, Elena Ribakovsky, MD, Ronit Yerushalmi, MD, Arnon Nagler, MD

Blood (2007) 110 (11): 1650.

https://doi.org/10.1182/blood.V110.11.1650.1650

Published: 2007

Journal Articles

Reduced-Intensity Conditioning Is Associated with Shorter Duration of Chronic GVHD Than Myeloablative Conditioning and Provides Very Good Quality of Life for Long-Term Survivors after Allogeneic Stem Cell Transplantation.

Avichai Shimoni, MD, Izhar Hardan, MD, Noga Shem-Tov, MD, Avital Rand, RN, Elena Ribakovsky, MD, Ronit Yerushalmi, MD, Arnon Nagler, MD

Blood (2007) 110 (11): 1668.

https://doi.org/10.1182/blood.V110.11.1668.1668

Published: 2007

Journal Articles

Treatment of Donor Graft Failure with Autologous or Allogenenic Stem-Cell Boost or a Second Allogeneic Transplant Based on Chimerism Testing.

Avichai Shimoni, MD, Noga Shem-Tov, MD, Avital Rand, RN, Elena Ribakovsky, MD, Ronit Yerushalmi, MD, Izhar Hardan, MD, Arnon Nagler, MD

Blood (2007) 110 (11): 2998.

https://doi.org/10.1182/blood.V110.11.2998.2998

Published: 2007

NARROW

Cyclosporine and Methotrexate Compared with Cyclosporine and Mycophenolate Mofetil as GVHD Prevention Regimens In Allogeneic Stem-Cell Transplantation From Unrelated Donors; Relative Outcomes Are Dependant on Disease Status at Transplantation

Fludarabine and Treosulfan Conditioning for Allogeneic Stem-Cell Transplantation; a Dose- Intense Regimen with Limited Toxicity.

Second Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine Treosulfan Conditioning Regimen in Patients Previously Treated with Busulfan-Based Regimens; Myeloablation with Acceptable Toxicity.

Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation (SCT) with Fludarabine and Intravenous Busulfan Is Associated with Improved Toxicity Profile and Longer Survival Than Conditioning with Fludarabine and Melphalan in Patients with Chemo-Sensitive Hematological Malignancies.

Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC).

Reduced-Intensity Conditioning Is Associated with Shorter Duration of Chronic GVHD Than Myeloablative Conditioning and Provides Very Good Quality of Life for Long-Term Survivors after Allogeneic Stem Cell Transplantation.

Treatment of Donor Graft Failure with Autologous or Allogenenic Stem-Cell Boost or a Second Allogeneic Transplant Based on Chimerism Testing.

Email alerts

ASH Publications

American Society of Hematology

Cyclosporine and Methotrexate Compared with Cyclosporine and Mycophenolate Mofetil as GVHD Prevention Regimens In Allogeneic Stem-Cell Transplantation From Unrelated Donors; Relative Outcomes Are Dependant on Disease Status at Transplantation

Fludarabine and Treosulfan Conditioning for Allogeneic Stem-Cell Transplantation; a Dose- Intense Regimen with Limited Toxicity.

Second Allogeneic Hematopoietic Stem-Cell Transplantation Using Fludarabine Treosulfan Conditioning Regimen in Patients Previously Treated with Busulfan-Based Regimens; Myeloablation with Acceptable Toxicity.

Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation (SCT) with Fludarabine and Intravenous Busulfan Is Associated with Improved Toxicity Profile and Longer Survival Than Conditioning with Fludarabine and Melphalan in Patients with Chemo-Sensitive Hematological Malignancies.

Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC).

Reduced-Intensity Conditioning Is Associated with Shorter Duration of Chronic GVHD Than Myeloablative Conditioning and Provides Very Good Quality of Life for Long-Term Survivors after Allogeneic Stem Cell Transplantation.

Treatment of Donor Graft Failure with Autologous or Allogenenic Stem-Cell Boost or a Second Allogeneic Transplant Based on Chimerism Testing.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only